Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ADVM |
---|---|---|
09:32 ET | 3034 | 7.315 |
09:34 ET | 100 | 7.315 |
09:38 ET | 100 | 7.3499 |
09:39 ET | 1057 | 7.31 |
09:45 ET | 100 | 7.4 |
09:54 ET | 10172 | 7.28 |
09:56 ET | 140 | 7.26 |
09:57 ET | 100 | 7.26 |
10:01 ET | 100 | 7.26 |
10:03 ET | 9294 | 7.21 |
10:06 ET | 5901 | 7.18 |
10:08 ET | 1271 | 7.24 |
10:10 ET | 200 | 7.18 |
10:12 ET | 400 | 7.215 |
10:14 ET | 458 | 7.215 |
10:17 ET | 1871 | 7.185 |
10:19 ET | 100 | 7.16 |
10:21 ET | 10107 | 7.08 |
10:24 ET | 37736 | 6.9999 |
10:26 ET | 300 | 6.9 |
10:28 ET | 8276 | 6.9092 |
10:30 ET | 1863 | 6.91 |
10:32 ET | 378 | 6.9 |
10:33 ET | 2075 | 6.88 |
10:35 ET | 300 | 6.87 |
10:37 ET | 1223 | 6.91 |
10:39 ET | 328 | 6.94 |
10:42 ET | 575 | 6.9565 |
10:44 ET | 1069 | 6.9121 |
10:51 ET | 4489 | 6.8692 |
10:53 ET | 1600 | 6.82 |
10:55 ET | 300 | 6.82 |
10:57 ET | 400 | 6.835 |
11:00 ET | 100 | 6.82 |
11:02 ET | 100 | 6.82 |
11:04 ET | 2258 | 6.8 |
11:06 ET | 200 | 6.76 |
11:13 ET | 300 | 6.77 |
11:15 ET | 744 | 6.78 |
11:20 ET | 100 | 6.79 |
11:22 ET | 1924 | 6.9 |
11:24 ET | 547 | 6.9095 |
11:27 ET | 200 | 6.87 |
11:29 ET | 100 | 6.875 |
11:31 ET | 1146 | 6.826 |
11:33 ET | 200 | 6.78 |
11:36 ET | 200 | 6.78 |
11:38 ET | 1620 | 6.73 |
11:47 ET | 2610 | 6.735 |
11:49 ET | 100 | 6.7334 |
12:02 ET | 500 | 6.7596 |
12:03 ET | 100 | 6.7599 |
12:05 ET | 100 | 6.73 |
12:09 ET | 2700 | 6.69 |
12:18 ET | 1137 | 6.7043 |
12:20 ET | 1931 | 6.679 |
12:21 ET | 200 | 6.68 |
12:23 ET | 630 | 6.6776 |
12:25 ET | 300 | 6.69 |
12:27 ET | 1100 | 6.71 |
12:34 ET | 1733 | 6.701 |
12:36 ET | 400 | 6.71 |
12:41 ET | 2150 | 6.7199 |
12:43 ET | 250 | 6.7178 |
12:45 ET | 1041 | 6.7 |
12:50 ET | 700 | 6.68 |
12:57 ET | 500 | 6.67 |
12:59 ET | 1000 | 6.68 |
01:03 ET | 200 | 6.68 |
01:06 ET | 683 | 6.65 |
01:10 ET | 100 | 6.62 |
01:12 ET | 100 | 6.62 |
01:15 ET | 2153 | 6.59 |
01:17 ET | 1045 | 6.6199 |
01:19 ET | 7280 | 6.74 |
01:21 ET | 1930 | 6.75 |
01:24 ET | 300 | 6.75 |
01:26 ET | 200 | 6.75 |
01:28 ET | 679 | 6.71 |
01:30 ET | 100 | 6.73 |
01:32 ET | 600 | 6.73 |
01:35 ET | 585 | 6.77 |
01:37 ET | 2794 | 6.79 |
01:39 ET | 800 | 6.85 |
01:42 ET | 1000 | 6.87 |
01:44 ET | 3785 | 6.87 |
01:46 ET | 10061 | 6.75 |
01:50 ET | 129 | 6.6837 |
01:51 ET | 200 | 6.69 |
01:55 ET | 711 | 6.63 |
01:57 ET | 25988 | 6.73 |
02:02 ET | 300 | 6.6 |
02:04 ET | 100 | 6.6 |
02:06 ET | 5700 | 6.71 |
02:11 ET | 100 | 6.67 |
02:13 ET | 1100 | 6.69 |
02:15 ET | 400 | 6.66 |
02:24 ET | 500 | 6.66 |
02:29 ET | 2400 | 6.68 |
02:31 ET | 1628 | 6.704 |
02:38 ET | 100 | 6.67 |
02:40 ET | 100 | 6.65 |
02:42 ET | 300 | 6.67 |
02:56 ET | 400 | 6.69 |
02:58 ET | 100 | 6.67 |
03:12 ET | 750 | 6.65 |
03:14 ET | 200 | 6.61 |
03:18 ET | 2122 | 6.65 |
03:20 ET | 100 | 6.65 |
03:21 ET | 300 | 6.65 |
03:25 ET | 709 | 6.66 |
03:27 ET | 1450 | 6.663 |
03:30 ET | 150 | 6.675 |
03:32 ET | 2218 | 6.69 |
03:34 ET | 200 | 6.67 |
03:36 ET | 100 | 6.67 |
03:38 ET | 100 | 6.67 |
03:39 ET | 3218 | 6.67 |
03:41 ET | 2964 | 6.665 |
03:43 ET | 1100 | 6.6797 |
03:45 ET | 2000 | 6.67 |
03:48 ET | 748 | 6.66 |
03:50 ET | 4590 | 6.6499 |
03:52 ET | 2020 | 6.63 |
03:54 ET | 1638 | 6.62 |
03:56 ET | 7341 | 6.62 |
03:57 ET | 3181 | 6.6 |
03:59 ET | 12059 | 6.59 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Adverum Biotechnologies Inc | 136.8M | -0.6x | --- |
Omega Therapeutics Inc | 122.4M | -1.3x | --- |
Sagimet Biosciences Inc | 126.1M | -3.2x | --- |
Adlai Nortye Ltd | 124.4M | -0.5x | --- |
Kodiak Sciences Inc | 137.1M | -0.6x | --- |
Yubo International Biotech Ltd | 130.6M | -103.9x | --- |
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $136.8M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 20.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.05 |
EPS | $-10.23 |
Book Value | $8.23 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.